Evofem Biosciences Resubmits New Drug Application to U.S. FDA for Amphora(R) for the Prevention of Pregnancy

Submission Supported by Phase 3 AMPOWER DataFDA Decision Anticipated Within Six MonthsSAN DIEGO, Nov. 26, 2019 -- (Healthcare Sales & Marketing Network)-- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today ...Biopharmaceuticals
Evofem Biosciences, Amphora